New Covid vaccines from Pfizer, Moderna and Novavax will likely protect against Eris variant
Publishing timestamp: 2023-08-18 10:38:16
Summary
The article discusses how the new Covid vaccines from Pfizer, Moderna, and Novavax are likely to provide protection against the new "Eris" variant, which is currently the dominant strain of the virus in the US. The vaccines have been designed to target the omicron subvariant XBB.1.5, which is slowly declining nationwide. Health experts and initial data suggest that the new shots will still be effective against Eris and other widely circulating variants. However, the vaccines are still awaiting approval from the FDA and will not be available to the public for another month or so. The arrival of these vaccines offers reassurance to Americans as cases and hospitalizations due to Covid variants increase slightly but remain below the peak seen last summer. The article also mentions that Eris does not appear to pose a significant threat and is not expected to cause a huge wave of Covid cases like previous strains. The new vaccines are expected to provide protection against Eris due to its similarity in genetic makeup to the XBB.1.5 strain. Data from the three companies, Moderna, Pfizer, and Novavax, support the effectiveness of their updated vaccines against Eris. The article concludes by stating that while some Americans may consider getting currently available Covid boosters, most people can afford to wait for the new vaccines.
Sentiment: NEUTRAL
Keywords: business news, biotech and pharmaceuticals, business, biotechnology, covid-19, immunizations, pfizer inc, coronavirus, breaking news, moderna inc, pharmaceuticals, novavax inc, vaccinations, science, covid-19 vaccine rollout, health care industry,
Source: https://www.cnbc.com/2023/08/18/covid-new-vaccines-will-likely-protect-against-eris-variant.html